Tom Shea, Meitheal Pharmaceuticals CEO
June 27, 2023 10:48 AM EDT
Deals
R&D

Xen­tria and Meitheal ink li­cens­ing deal for rare lung dis­ease treat­ment in North Amer­i­ca

Tyler Patchen

News Reporter

Xen­tria will li­cense its ex­per­i­men­tal pul­monary sar­coido­sis drug to Meitheal Phar­ma­ceu­ti­cals in a deal worth up to $680 mil­lion.

Meitheal spun out Xen­tria in 2020 …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

A service from the Financial Times